Middle East Current Psychiatry
February 10, 2022
El Hassan Ouanouche, Hicham Elmostafi, Naoufal Amarat et al.
In addition to the biological plausibility widely described through a very large number of studies, the causal link between cannabis uses and schizophrenia disorders has become illicit internationally and given the scarcity of similar studies in Morocco. Our study consists of a prospective descriptive study in the psychiatric department of the Moulay ben Abdallah Hospital in Essaouira. The...
Frontiers in Aging Neuroscience
February 10, 2022
K. Watson, Angela D Bryan, R. Thayer et al.
Several lines of evidence suggest that older adults (aged 65+) sharply increased their cannabis use over the last decade, highlighting a need to understand the effects of cannabis in this age group. Pre-clinical models suggest that cannabinoids affect the brain and cognition in an age-dependent fashion, having generally beneficial effects on older animals and deleterious effects on younger...
Stroke
February 10, 2022
Fernando D. Testai, Philip B. Gorelick, Hugo J. Aparicio et al.
50 citations
Marijuana is perceived as a harmless drug, and its recreational use has gained popularity among young individuals. The concentration of active ingredients in recreational formulations has gradually increased over time, and high-potency illicit cannabinomimetics have become available. Thus, the consumption of cannabis in the general population is rising. Data from preclinical models demonstrate...
American Journal of Psychiatry
February 2022
Kevin P Hill, Mark S. Gold, Charles B. Nemeroff et al.
The United States is in the midst of rapidly changing laws regarding cannabis. The increasing availability of cannabis for recreational and medical use requires that mental health clinicians be knowledgeable about evidence to be considered when counseling both patients and colleagues. In this review, the authors outline the evidence from randomized double-blind placebo-controlled trials for...
International Journal of Drug Policy
February 2022
Pieter E Oomen, Dominique Schori, Karsten Tögel-Lins et al.
European drug checking services exchange information on drug trends within the Trans European Drug Information (TEDI) network, allowing monitoring and coordination of responses. Starting in Spring 2020, several services detected the synthetic cannabinoid receptor agonist MDMB-4en-PINACA in adulterated low-THC cannabis products. Cannabis products suspected of adulteration were analyzed for the...
Psychophysiology
February 2022
Elisa Pabon, Frederica Rockwood, Greg J Norman et al.
Cannabis is the most commonly used psychotropic drug in the United States, after alcohol. Despite its apparent sedative and calming effects, cannabis and its main psychoactive constituent, ∆9 -tetrahydrocannabinol (THC) can produce serious adverse effects including tachycardia and anxiety. These effects can be especially pronounced in women, who remain underrepresented in clinical cannabinoid...
medRxiv
January 31, 2022
Deepak Cyril D’souza, Justin Raj, Suhas Ganesh et al.
preprint
Abstract Introduction Cannabis use has been associated with several psychosis outcomes including acute and persistent psychosis termed Cannabis Induced Psychotic Disorder (CIPD). The clinical and cognitive profile, course of CIPD, and the extent to which it is different from psychosis unrelated to cannabis exposure (PsyNoCan) is not clear. Methods The acute presentation and short-term (∼4...
Frontiers in Psychiatry
January 21, 2022
Melina Wiedmann, Sören Kuitunen-Paul, Lukas A Basedow et al.
5 citations
ObjectivesBoth substance use, on the one hand, and the first signs of psychosis, on the other, commonly begin in adolescence. Adolescents with substance use disorder (SUD) frequently show recreational use of cannabis and 3,4-methylenedioxymethamphetamine (MDMA). When attenuated psychotic symptoms (APS) occur during the course of SUD, they are commonly attributed to the cannabis use, neglecting...
Addiction
January 19, 2022
Laura Dellazizzo, Stéphane Potvin, S. Giguère et al.
BACKGROUND Cannabis is among the most consumed psychoactive substances world-wide. Considering changing policy trends regarding the substance, it is crucial to understand more clearly its potential acute and residual adverse effects from a public health viewpoint. Cognitive function is one of the targeted areas with conflicting findings. This meta-review measured the magnitude of acute and...
Schizophrenia Research: Cognition
January 5, 2022
Christopher Dawes, Declan Quinn, Andrea Bickerdike et al.
Aberrant salience processing may underlie the link between cannabis and psychosis, as posited in individuals with schizophrenia or high schizotypy. We investigated the relative effects of cannabis use, schizotypy status, and self-reported aberrant salience experiences on salience processing, measured using a latent inhibition (LI) task (Granger et al., 2016), in a non-clinical population. A...
Journal of Cannabis Research
January 4, 2022
J. Kruger, Daniel J. Kruger
Background Products containing delta-8-THC became widely available in most of the USA following the 2018 Farm Bill and by late 2020 were core products of hemp processing companies, especially where delta-9-THC use remained illegal or required medical authorization. Research on experiences with delta-8-THC is scarce, some state governments have prohibited it because of this lack of knowledge....
Frontiers in Neuroscience
2022
Isaac Ostlund, Michael Von Gunten, Calvin Smith et al.
The ventral tegmental area (VTA) mediates incentive salience and reward prediction error through dopamine (DA) neurons that are regulated by local VTA GABA neurons. In young mice, VTA GABA cells exhibit a form of synaptic plasticity known as long-term depression (LTD) that is dependent on cannabinoid 1 (CB1) receptors preceded by metabotropic glutamate receptor 5 (mGluR5) signaling to induce...
Frontiers in Psychiatry
2022
Sarah Beggiato, Alessandro Ieraci, Mariachiara Zuccarini et al.
Cannabis abuse during adolescence is a risk factor for cognitive impairments in psychiatric disorders later in life. To date, the possible causal relationship between cannabinoids, kynurenic acid (KYNA; i.e., a neuroactive metabolite of tryptophan degradation) and cognition has not been investigated in adolescence. Early exposure to delta 9-tetrahydrocannabinol (THC; i.e., the main psychotropic...
2022
Raphael Carvalho Beraldo
A esquizofrenia é uma doença complexa que apresenta grande espectro de sintomas. Entre eles estão os sintomas positivos, negativos e cognitivos que interferem de forma determinante na vida do indivíduo, caracterizando-se uma doença de grande estigma na sociedade. Por ser complexa, sua etiologia ainda é pouco elucidada se baseando, atualmente, em duas principais teorias: dopaminérgica e a do...
eNeuro
2022
Mohammed H Sarikahya, Samantha Cousineau, Marta De Felice et al.
Despite increased prevalence of maternal cannabis use, little is understood regarding potential long-term effects of prenatal cannabis exposure (PCE) on neurodevelopmental outcomes. While neurodevelopmental cannabis exposure increases the risk of developing affective/mood disorders in adulthood, the precise neuropathophysiological mechanisms in male and female offspring are largely unknown....
Neurobiology of Disease
January 2022
Aliza A Le, Julian Quintanilla, Mohammad Amani et al.
There is evidence that cannabis use during adolescence leads to memory and cognitive problems in young adulthood but little is known about effects of early life cannabis exposure on synaptic operations that are critical for encoding and organizing information. We report here that a 14-day course of daily Δ9-tetrahydrocannabinol treatments administered to adolescent rats and mice (aTHC) leads to...
Abstracts from the 2021 Virtual Scientific Meeting of the Research Society on Marijuana July 23rd, 2021
2022
Ari P. Kirshenbaum, C. Lewis, A. Kaplan
The degree to which frequent users of cannabis experience cognitive impairment from acute self-administration has been questioned on the basis of behavioral tolerance to THC. "Indicator" is a downloadable mobile software app that assesses cognitive, perceptual, and motor skills using a variety of brief videogames. In the course of one month (April 2021), the app was used by 199 adult users who...
Journal of Psychiatric Research
2022
E. Kline, M. Ferrara, Fang-Yong Li et al.
Cannabis has been implicated as both a potential cause and adverse prognostic factor in psychotic disorders. Investigating the contributory role of cannabis toward the overall burden of psychotic illnesses may represent an important step toward psychosis prevention and treatment. The current study samples consecutive admissions (N = 246) to two community based first-episode psychosis services...
Psychiatry Research
2022
Lauren V. Moran, E. Tsang, D. Öngür et al.
The 2017 National Inpatient Sample database was utilized to investigate the association between cannabis legalization in the United States and hospitalizations for psychosis associated with cannabis use. We compared the odds of hospital discharges for psychosis associated with cannabis use in adults between the Pacific census division (where most states legalized recreational cannabis use) and...
PLoS One
2022
Hollis C Karoly, Mark A. Prince, Noah N Emery et al.
Cannabis is commonly used among people who drink alcohol, yet evidence on acute effects of co-use is conflicting. Two important variables that may influence the effects of cannabis and alcohol are cannabinoid content (i.e., the ratio of cannabidiol [CBD] and 9-tetrahydrocannabinol [THC]) as well as the order of use (i.e., cannabis before alcohol vs. alcohol before cannabis). Research is mixed...